GeoVax Labs, Inc.
GOVXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How GOVX's past catalysts played out
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
COVID-19 Infection
COVID-19 Vaccine
COVID-19 Infection
Ad/PNP
Recurrent Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 | Phase 2 | COVID-19 Infection | - | - |
COVID-19 Vaccine | Phase 2 | COVID-19 Infection | - | - |
Ad/PNP | Phase 2 | Recurrent Head and Neck Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in GeoVax Labs, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in GeoVax Labs, Inc.'s (GOVX) pipeline across Phase 2. Its lead program is Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GeoVax Labs, Inc.'s next FDA catalyst?→
GeoVax Labs, Inc.'s (GOVX) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GOVX biotech catalysts?→
Add GOVX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GeoVax Labs, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.